GlaxoSmithKline, Novartis pharmaceuticals news
GlaxoSmithKline disclosed in its 3Q14 earnings call that it reshuffled its executive management as it prepares to integrate the vaccines business it is acquiring from Novartis in an asset-swapping deal announced in April. Moncef Slaoui, previously chairman of global pharmaceuticals R&D and vaccines, will become chairman of global vaccines. Patrick Vallance will remain president of pharmaceutical R&D and take sole responsibility for GSK's R&D in pharmaceuticals. The two executives previously shared pharmaceutical R&D responsibilities. Slaoui remains a member of GSK's board.
On the commercial side, GSK named Abbas Hussain president of global pharmaceuticals. Hussain, who will head up commercial operations in all regions, including China, previously led GSK's commercial operations in Europe, Japan and emerging markets. Deirdre Connelly will remain in charge of U.S. commercial operations as president of North America pharmaceuticals. ...